NomosLogic at BIO International 2026: San Diego, June 22-25
NomosLogic will be at the BIO International Convention in San Diego, June 22 to 25, 2026. The four days at the San Diego Convention Center bring together roughly 20,000 leaders across biotechnology, pharmaceuticals, regulation, and investment. We are showing up to participate in the conversations that matter, to meet the people building the next decade of the field, and to open partnership discussions with the operators whose work compounds with ours.
This is the right conference, in the right year, for the work we are doing.
Why BIO 2026 Matters
The 2026 program lands at a structural inflection. AI applied to health and digital health, personalized medicine, next-generation biotherapeutics, intellectual property, regulation, and translational research are all on the agenda, and all of them are at the point where the standards being set this year will define how the field operates for the next ten. The agencies are codifying. The capital markets are recalibrating. The institutional buyers are tightening what they accept as production-ready. The conversations happening in San Diego in June will shape decisions that matter long after the convention closes.
The deterministic standard for clinical decision infrastructure is one of those decisions, and we intend to be substantive in the conversations that determine where it lands.
What We Bring to the Conversation
The platform is in production today, serving four execution domains from one sovereign substrate: clinical genomics, consumer genomics, payer infrastructure, and pharma research. The underlying engines run at scale. 17.4 million anchored molecular reference assets. 1.26 million Clinical Logic Objects. 362 FDA drug-gene mandates covered. Sub-30-second deterministic genome resolution. Sub-90-second multi-omic fusion across genomic and standard clinical lab data.
The architectural commitment underneath the platform is what makes it different. Every clinical assertion is rule-based, reproducible, and SHA-256 anchored to the rule version that produced it. AI lives at the interpretation and communication surface where it belongs. The clinical decision layer is deterministic. That distinction is not cosmetic. It is the structural property that makes the platform auditable under FDA scrutiny, defensible in clinical practice, and resilient through the regulatory and capital-market shifts the field is moving into.
Who We Want to Meet
The four days are short and the convention is large. We are coming with a clear list of conversations worth having.
Pharma and biotech research teams working on programs where pharmacogenomic decision support, multi-modal data fusion, or deterministic variant interpretation would change trial design, candidate prioritization, or post-market surveillance. The Hardy Bridge translation layer and the COVENANT variant resolution engine were built for exactly these workflows.
Health systems and clinical labs evaluating how to bring auditable, reproducible interpretation infrastructure into their operations without compromising the clinical credibility that institutional buyers actually pay for. The integration surface ingests standard genomic, chemistry, hematology, urinalysis, and therapeutic drug monitoring data, and delivers the synthesis through SMART on FHIR directly into the EHR.
Payer organizations thinking about how pharmacogenomic-guided prescribing changes the actuarial picture on adverse drug events, polypharmacy, and avoidable hospitalizations. The economics are real. The infrastructure that makes them legible to a payer organization is the part that has been missing.
Investors and corporate development teams mapping the deterministic infrastructure category. NomosLogic operates in a category most diligence frameworks do not yet have a clean comparison set for, which is the structural signal that the category is real and the entrants are few.
Thought leaders, policy voices, scientists, authors, and media working on the regulatory framework for clinical AI, pharmacogenomic standards, IP protection in molecular medicine, and the broader question of how the next generation of clinical decision infrastructure should be governed.
How to Connect
For partnership discussions, sales conversations, and general business development, reach Jai DeJong, SVP of Business Development and Sales, at jai.dejong@nomoslogic.com.
For CEO-to-CEO conversations, scientist-to-scientist conversations on the underlying science, author and editorial conversations, and media inquiries, reach Matt Hardy directly at matt.hardy@nomoslogic.com.
We are scheduling structured BIO Partnering meetings through the official platform and holding additional time for substantive conversations that come through direct outreach.
See you in San Diego.
#BIO2026 #BIOInternational #SanDiego #ClinicalGenomics #Pharmacogenomics #PrecisionMedicine #DeterministicConvergence #MolecularMedicine #Biotech #ClinicalAI #PatientCare #HealthInnovation #NomosLogic
